
Antoni Martinez-Rubio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3386987/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impact of prescription patterns of antithrombotic treatment on atrial fibrillation-related ischemic stroke. Current Medical Research and Opinion, 2021, 37, 357-365.	1.9	5
2	World Heart Federation Roadmap on Atrial Fibrillation – A 2020 Update. Global Heart, 2021, 16, 41.	2.3	39
3	Improvement in Atrial Fibrillation-Related Symptoms After Cardioversion: Role of NYHA Functional Class and Maintenance of Sinus Rhythm. Clinical Interventions in Aging, 2021, Volume 16, 739-745.	2.9	4
4	Coronavirus Disease 2019 and Cardiac Arrhythmias. European Cardiology Review, 2020, 15, e66.	2.2	6
5	Anemia and iron deficiency in heart failure: a review of echocardiographic features. Echocardiography, 2019, 36, 585-594.	0.9	12
6	Antiarrhythmic drugs–clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace, 2018, 20, 731-732an.	1.7	144
7	Key Recent Advances in Atherosclerosis Treatment with Modern Lipid-lowering Drugs: The New Frontier with PCSK9 Inhibitors. European Cardiology Review, 2017, 12, 30.	2.2	0
8	Cardiovascular Pharmacotherapies Focus: Are low doses of direct-acting oral anticoagulants justified and appropriate in patients with nonvalvular atrial fibrillation?. European Cardiology Review, 2016, 11, 115-117.	2.2	4
9	Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation: Assessment, Monitoring and Treatment Reversal. European Cardiology Review, 2016, 11, 118.	2.2	5
10	Cardiovascular Pharmacotherapies Focus: Are low doses of direct-acting oral anticoagulants justified and appropriate in patients with nonvalvular atrial fibrillation?. European Cardiology Review, 2016, 11, 115-117.	2.2	3
11	Gender Differences in Patients with Atrial Fibrillation Undergoing Electrical Cardioversion. Journal of Women's Health, 2015, 24, 466-470.	3.3	15
12	Current Evidence for New Oral Anticoagulants in the Treatment of Nonvalvular Atrial Fibrillation: Comparison of Substudies. Revista Espanola De Cardiologia (English Ed), 2015, 68, 185-189.	0.6	2
13	New Oral Anticoagulants vs Vitamin K Antagonists: Benefits for Health-Related Quality of Life in Patients with Atrial Fibrillation. International Journal of Medical Sciences, 2014, 11, 680-684.	2.5	26
14	Patent Foramen Ovale Causing Severe Hypoxemia Due to Right-to-left Shunting in Patients Without Pulmonary Hypertension. Clinical Suspicion Clues for Diagnosis and Treatment. Revista Espanola De Cardiologia (English Ed), 2014, 67, 324-325.	0.6	1
15	Sobre el coste-efectividad de dabigatrán. Respuesta. Revista Espanola De Cardiologia, 2013, 66, 513.	1.2	Ο
16	On the Cost-effectiveness of Dabigatran. Response. Revista Espanola De Cardiologia (English Ed), 2013, 66, 513.	0.6	0
17	The fully automatic external cardioverter defibrillator: reality of a new meaningful scenario for in-hospital cardiac arrests. Expert Review of Medical Devices, 2005, 2, 33-39.	2.8	1
18	The automatic external cardioverter-defibrillator. Indian Pacing and Electrophysiology Journal, 2004, 4. 114-21.	0.6	0